Purple Biotech's IM1240 shows anti-tumor activity in resistant cancer models
PPBT•Purple Biotech presented preclinical results showing IM1240 killed patient-derived lung, head and neck, and bladder cancers resistant to immunotherapy. The company said its capped design reduced systemic cytokine release and prolonged exposure in nonhuman primates compared with an uncapped variant.
1. Preclinical findings
Purple Biotech presented IM1240 results at the EORTC-NCI-AACR Symposium in Barcelona on November 20, 2026. The antibody demonstrated tumor-killing activity in patient-derived lung, head and neck, and bladder cancers resistant to immunotherapy; blocking the NKG2A immune checkpoint improved tumor killing beyond T-cell engagement alone.
2. Design and next steps
In nonhuman primates, IM1240's capped design reduced systemic cytokine release and prolonged exposure compared with an uncapped variant. The findings support advancing IM1240 toward clinical testing.




